I think selling Zenith Epigenetics being a private enterprise via  a CVR  deal or alright buyout deal is easier for a BP  to buy than RVX that is public  and has a market cap too small for a proper multi Billion buyout  valuation .  I could see  Zenith buyout or partnership deal as a catalyst for an RVX deal as it would establish a new epigenetics company valuation,   Right now the only comparable public epigentics company is Constellation Pharmaceutical with enterprise value of $1.4 Bill US or $1.8 Billion CAD so thats a good start for a buyout price or partnership CVR deal.  Its been 7 years since inception, DM its about time you get it done!!!